companiesCompany
Suzhou Zelgen Biopharmaceuticals
aka Zelgen, 泽璟制药
Zelgen developed donafenib, the deuterated sorafenib that beat the original in first-line liver cancer and was approved in China in 2021.
Overview
Donafenib (Zepsun) approved 2021 for HCC and 2022 for thyroid cancer; jaktinib (JAK inhibitor) for myelofibrosis; recombinant human thrombin. One of the first companies listed on Shanghai's STAR Market before profitability.
Headquarters
Suzhou, CN
Scorecard
All companies#99of 680 companies, score 27
- approved products +6
- targets +4
- modalities +2
- regions +1
- registry trials +14
1 approved, 0 in phase 3, 0 earlier, 2 targets, 47 registry studies. Formula on the scorecards page.
Type
biotech · 688266.SS
Stage
Public
Website
Founded
2009
Pages like this
not linked directly; found by shared links- PersonShukui Qin
Shares ZGDH3 (donafenib vs sorafenib), Donafenib and the tag china.